New clinical trials with vitamin D and analogs in renal disease

Research output: Contribution to journalComment/debate

6 Scopus citations

Abstract

Two new clinical trials highlight refinements in the use of vitamin D and its analogs in the treatment of secondary hyperparathyroidism in end-stage renal disease (ESRD), and the treatment of proteinuria in diabetics. In patients with ESRD, alfacalcidol is as effective as paricalcitol in suppressing parathyroid hormone; the occurrence of hypercalcemia and hyperphosphatemia is infrequent and similar with the two analogs. Oral cholecalciferol reduces albuminuria and urinary transforming growth factor-β1 in patients with type 2 diabetes mellitus and proteinuria.

Original languageEnglish (US)
Pages (from-to)793-796
Number of pages4
JournalKidney international
Volume80
Issue number8
DOIs
StatePublished - Oct 2 2011

    Fingerprint

ASJC Scopus subject areas

  • Nephrology

Cite this